Cutanos has created a highly modular antigen delivery platform called LC-TDS that specifically targets Langerhans cells, a type of immune cell. This platform reduces the drug load, increases efficiency, and provides unprecedented control over antigen delivery. The company's systems use small molecule ligands to facilitate the uptake of nanoparticles by Langerhans cells, enabling medical practitioners to trigger immune responses against foreign pathogens and tumor antigens. Cutanos aims to develop new immunotherapies, including anti-viral vaccines and treatments for autoimmune diseases.